Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Kinase-targeting small-molecule inhibitors and emerging bifunctional molecules
Georg L. Goebel, Xiaqiu Qiu, Peng Wu
Trends in Pharmacological Sciences (2022) Vol. 43, Iss. 10, pp. 866-881
Closed Access | Times Cited: 28

Showing 1-25 of 28 citing articles:

Targeting Extracellular Signal-Regulated Protein Kinase 1/2 (ERK1/2) in Cancer: An Update on Pharmacological Small-Molecule Inhibitors
Leilei Fu, Siwei Chen, Gu He, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 20, pp. 13561-13573
Closed Access | Times Cited: 28
Development and therapeutic potential of adaptor-associated kinase 1 inhibitors in human multifaceted diseases
Xin Xin, Yue Wang, Lele Zhang, et al.
European Journal of Medicinal Chemistry (2023) Vol. 248, pp. 115102-115102
Closed Access | Times Cited: 17
Overcoming cancer therapy resistance: From drug innovation to therapeutics
Jinrui Wei, Meng‐Yi Lu, Tian‐Hua Wei, et al.
Drug Resistance Updates (2025) Vol. 81, pp. 101229-101229
Closed Access
Computational Development of Allosteric Peptide Inhibitors Targeting LIM Kinases as a Novel Therapeutic Intervention
Nagarajan Hemavathy, Sampathkumar Ranganathan, Umashankar Vetrivel, et al.
Cell Biochemistry and Biophysics (2025)
Closed Access
Anticancer and anti-inflammatory effects of novel ethyl pyrazole derivatives having sulfonamide terminal moiety
Mohammed S. Abdel‐Maksoud, S. A. Nasser, Rasha M. Hassan, et al.
Bioorganic Chemistry (2024) Vol. 153, pp. 107825-107825
Closed Access | Times Cited: 3
Profiling of small‐molecule necroptosis inhibitors based on the subpockets of kinase–ligand interactions
Lijuan Xu, Chunlin Zhuang
Medicinal Research Reviews (2023) Vol. 43, Iss. 6, pp. 1974-2024
Closed Access | Times Cited: 8
Isoform-selective targeting of PI3K: time to consider new opportunities?
Davide Cirillo, Marta Diceglie, Marc Nazaré
Trends in Pharmacological Sciences (2023) Vol. 44, Iss. 9, pp. 601-621
Closed Access | Times Cited: 8
Insights into the post-translational modifications in heart failure
Xudong Zhang, Yan Wang, Huaping Li, et al.
Ageing Research Reviews (2024) Vol. 100, pp. 102467-102467
Closed Access | Times Cited: 2
Targeting Ribonucleases with Small Molecules and Bifunctional Molecules
Lydia Borgelt, Peng Wu
ACS Chemical Biology (2023) Vol. 18, Iss. 10, pp. 2101-2113
Open Access | Times Cited: 6
Design, synthesis, and evaluation of new benzimidazole‏ ‏‎thiourea ‎derivatives as antitumor agents
Mohamed Abou-Taleb, Nadia S. El‐Gohary, Hazem A. Ghabbour, et al.
Archiv der Pharmazie (2023) Vol. 356, Iss. 11
Closed Access | Times Cited: 5
Profiling Cellular Morphological Changes Induced by Dual‐targeting PROTACs of Aurora Kinase and RNA‐binding Protein YTHDF2
Georg L. Goebel, Nicole Giannino, Philipp Lampe, et al.
ChemBioChem (2024)
Open Access | Times Cited: 1
[Review] The Landscape of Interferons in Health and Disease
Brent Brown, Chinua Imarogbe, Ingo Fricke
(2024)
Closed Access | Times Cited: 1
In Vitro Assessment of Inhibitory Effects of Kinase Inhibitors on CYP2C9, 3A and 1A2: Prediction of Drug-Drug Interaction Risk with Warfarin and Direct Oral Anticoagulants
Shasha Jin, Marie‐Noëlle Paludetto, Mika Kurkela, et al.
European Journal of Pharmaceutical Sciences (2024) Vol. 203, pp. 106884-106884
Open Access | Times Cited: 1
Development of Novel 1,3,4‐Trisubstituted Pyrazole Derivatives Bearing Sulfonamide Moiety as Anticancer Agents Targeting JNK Kinases
Asmaa A. Shams, Mohammed S. Abdel‐Maksoud, Ahmed A. B. Mohamed, et al.
ChemistrySelect (2024) Vol. 9, Iss. 40
Closed Access | Times Cited: 1
Exploration of drug repurposing for Mpox outbreaks targeting gene signatures and host-pathogen interactions
Saber İmani, Sargol Aminnezhad, Moslem Alikarami, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 1
The landscape of novel strategies for acute myeloid leukemia treatment: Therapeutic trends, challenges, and future directions
Ri Han Wu, Chen Zhu, Pei Han Yu, et al.
Toxicology and Applied Pharmacology (2023) Vol. 473, pp. 116585-116585
Closed Access | Times Cited: 4
Dr Jekyll and Mr Hyde: From Two Branches of Immune Response to Three Types of Interferon Response
Brent Brown
(2023)
Open Access | Times Cited: 4
An Update on Protein Kinases as Therapeutic Targets—Part II: Peptides as Allosteric Protein Kinase C Modulators Targeting Protein–Protein Interactions
Mulate Zerihun, Samuel J. S. Rubin, Shmuel Silnitsky, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 24, pp. 17504-17504
Open Access | Times Cited: 4
Mechanistic Insights into the Mechanism of Inhibitor Selectivity toward the Dark Kinase STK17B against Its High Homology STK17A
Chang Liu, Yichi Zhang, Yuqing Zhang, et al.
Molecules (2022) Vol. 27, Iss. 14, pp. 4655-4655
Open Access | Times Cited: 4
Revisiting Structure-activity Relationships: Unleashing the potential of selective Janus kinase 1 inhibitors
Mengyi Shan, Xuan Zhao, Peng Sun, et al.
Bioorganic Chemistry (2024) Vol. 149, pp. 107506-107506
Closed Access
Anticancer and Anti-Inflammatory Effects of Novel Ethyl Pyrazole Derivatives Having Sulfonamide Terminal Moiety
Mohammed S. Abdel‐Maksoud, Shaimaa Abd ElMoneim abdullah Nasser, Rasha M. Hassan, et al.
(2024)
Closed Access
Acquired resistance to tyrosine kinase targeted therapy: mechanism and tackling strategies
Defa Wu, Qian Sun, Hongjun Tang, et al.
Drug Resistance Updates (2024) Vol. 78, pp. 101176-101176
Closed Access
Tilting the Scales toward EGFR Mutant Selectivity: Expanding the Scope of Bivalent “Type V” Kinase Inhibitors
Florian Wittlinger, Surbhi P. Chitnis, Calvin D. Pham, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 23, pp. 21438-21469
Closed Access
Identification, biological evaluation, and crystallographic analysis of coumestrol as a novel dual-specificity tyrosine-phosphorylation-regulated kinase 1A inhibitor
Chao-Hsiang Peng, Tsong‐Long Hwang, Shao-Chi Hung, et al.
International Journal of Biological Macromolecules (2024), pp. 136860-136860
Open Access
Drug discovery processes: When and where the rubber meets the road
Susan M. Miller, Walter H. Moos, Barbara H. Munk, et al.
Elsevier eBooks (2023), pp. 339-415
Closed Access | Times Cited: 1
Page 1 - Next Page

Scroll to top